PTC Therapeutics’ Product Risdiplam Met Trial Endpoints for the Treatment of Spinal Muscular Atrophy

PTC Therapeutics Risdiplam Results for SMA
PTC Therapeutics (PTCT) has positive results from part 2 of the SUNFISH trial evaluating the safety and efficacy of the product risdiplam. The results demonstrate that the trial has met its primary endpoint of change from baseline after 1 year of treatment with risdiplam compared to placebo.

The change was measured by the Motor . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.